Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900232 | 1.00 | GSK3A (0.43) | GSK3AGSK3BHCRTR1HCRTR2EHMT2 | |
| SCHEMBL21563281 | 0.85 | GSK3A (0.53) | GSK3AGSK3BEHMT2SMOMEN1 | |
| SCHEMBL21563349 | 0.85 | GSK3A (0.53) | GSK3AGSK3BEHMT2SMOMEN1 | |
| SCHEMBL7906136 | 0.77 | HTR2C (0.46) | GSK3AGSK3BHCRTR1HCRTR2EHMT2 | |
| SCHEMBL13297796 | 0.74 | EHMT2 (0.49) | EHMT2SMOMEN1KMT2AALDH1A1 | |
| SCHEMBL25590783 | 0.74 | GAA (0.40) | GSK3AGSK3BEHMT2SMOMEN1 | |
| SCHEMBL3106820 | 0.73 | KMT2A (0.39) | GSK3AGSK3BEHMT2SMOMEN1 | |
| SCHEMBL7407552 | 0.73 | HCRTR2 (0.50) | HCRTR1HCRTR2EHMT2MEN1KMT2A | |
| SCHEMBL2265479 | 0.73 | HCRTR2 (0.50) | HCRTR1HCRTR2EHMT2MEN1KMT2A | |
| SCHEMBL102314 | 0.71 | EHMT2 (0.49) | EHMT2SMOMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049529-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192143-A1 | Substituted diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | GSK3A 1170/4885GSK3B 1301/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.